| 参考文献: |
1. Guo Ye, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4092-4092.2. Jisong Cui, et al. Method for treating head and neck cancer. WO2023088105A1. 2022-11-03 |